MedCAC Says PET Data Is Too Weak To Remove Registry Requirement
This article was originally published in The Gray Sheet
Executive Summary
CMS should maintain its data collection requirements for coverage of positron emission tomography for nine cancers, because the evidence linking PET to improved outcomes is still weak, the Medicare Evidence Development and Coverage Advisory Committee concluded at its Aug. 20 meeting
You may also be interested in...
Cancer Specialists Seek Fewer Restrictions On Medicare Coverage For PET
Oncologists and imaging device manufacturers are urging CMS not to restrict coverage for PET scans used to detect recurrence, monitor treatment or restage a cancer prognosis after its initial diagnosis
Cancer Specialists Seek Fewer Restrictions On Medicare Coverage For PET
Oncologists and imaging device manufacturers are urging CMS not to restrict coverage for PET scans used to detect recurrence, monitor treatment or restage a cancer prognosis after its initial diagnosis
CMS Proposes To Require Less Data Collection For Cancer PET Coverage
CMS plans to remove some of its coverage-with-evidence-development (CED) requirements for positron emission tomography scans for an array of cancer types